Feature

Is kratom the answer to the opioid crisis?


 


Dr. Goldberger, Dr. Levounis, Dr. Grundmann, and Dr. Holcomb had no disclosures. Dr. Galbis-Reig disclosed in his study that he is the owner of stock in GW Pharmaceuticals and Cortex Pharmaceuticals, Pfizer bonds, and has spousal ownership of stock in AbbVie, Abbott Pharma, and Hospira. Dr. Swogger and other authors of the systematic review reported serving as consultants for the American Kratom Association, as well as sponsors of other kratom products.

Pages

Recommended Reading

Opioid deaths in the ED increase nationally
MDedge Psychiatry
Opioid prescriptions got shorter in 2017
MDedge Psychiatry
Alcohol dependence may accelerate aging, frontal cortical deficits
MDedge Psychiatry
Interventions urged to stop rising NAS, stem Medicaid costs
MDedge Psychiatry
Congress tackles the opioid epidemic. But how much will it help?
MDedge Psychiatry
FDA wants data on role of flavored tobacco products in youth initiation
MDedge Psychiatry
MDedge Daily News: Stem cells may reverse premature menopause
MDedge Psychiatry
Early family intervention tied to reduced AUDs in Mexican American youth
MDedge Psychiatry
Cannabis users at highest psychosis risk may elect to quit
MDedge Psychiatry
Parents surveyed about underage drinking
MDedge Psychiatry